

Personal aging markers and ageotypes revealed by deep longitudinal profiling

Sara Ahadi^{1,2}, Wenyu Zhou^{1,2}, Sophia Miryam Schüssler-Fiorenza Rose¹, M. Reza Sailani¹, Kévin Contrepois¹, Monika Avina¹, Melanie Ashland¹, Anne Brunet¹ and Michael Snyder^{1*}

The molecular changes that occur with aging are not well understood^{1–4}. Here, we performed longitudinal and deep multiomics profiling of 106 healthy individuals from 29 to 75 years of age and examined how different types of ‘omic’ measurements, including transcripts, proteins, metabolites, cytokines, microbes and clinical laboratory values, correlate with age. We identified both known and new markers that associated with age, as well as distinct molecular patterns of aging in insulin-resistant as compared to insulin-sensitive individuals. In a longitudinal setting, we identified personal aging markers whose levels changed over a short time frame of 2–3 years. Further, we defined different types of aging patterns in different individuals, termed ‘ageotypes’, on the basis of the types of molecular pathways that changed over time in a given individual. Ageotypes may provide a molecular assessment of personal aging, reflective of personal lifestyle and medical history, that may ultimately be useful in monitoring and intervening in the aging process.

Aging is a universal process of physiological and molecular changes that are strongly associated with susceptibility to disease and ultimately death^{1–5}. Despite its importance and extensive analysis in model organisms, a comprehensive view of the molecular changes that occur during aging in humans is not known and understanding of the heterogeneity of the aging process at an individual level and over short actionable timescales is lacking.

Cross-sectional studies have revealed differences in telomeres and DNA methylation associated with age⁶. The latter has led to a description of a ‘molecular clock’ that is associated with chronological and biological age^{7,8}. Acceleration of the clock has been associated with human diseases. In addition to epigenetic markers, several clinical markers, such as cholesterol and glycosylated hemoglobin (HbA1c) levels, which are associated with metabolic disorders and type 2 diabetes, change with age^{9,10}. However, global monitoring of molecular profiles has not been performed, and thus, a comprehensive understanding of the changes in different pathways that occur within an individual and the ageotypes that exist in humans are not known. Even for individuals with type 2 diabetes and insulin resistance (IR; commonly associated with type 2 diabetes), the full pattern of changes that occur with age and intervention is not known. Understanding both patterns of aging and how IR is associated with age is ultimately important for targeted intervention.

We studied a cohort comprising 106 prediabetic and healthy individuals, extensively characterized for many parameters of glucose dysregulation, including fasting glucose, HbA1c, oral glucose tolerance tests¹¹ and IR using a steady-state plasma glucose (SSPG) test¹². The cohort (age range 29–75 years; median 55.74 years) was tracked with quarterly visits for up to 4 years, with additional samples acquired during periods of physiological stress, such as respiratory viral infections. The participants engaged in a total of 1,092

visits and samples were analyzed by seven omics assays (Fig. 1a). For each visit, we performed proteomics and metabolomics on plasma samples, transcriptome analysis on material from peripheral blood mononuclear cells and targeted cytokine assays using serum. Nasal and gut microbiomes were analyzed using 16S rRNA sequencing, providing information at the genus level, and exome sequencing was performed once using DNA from peripheral blood mononuclear cells. In addition, 51 clinical laboratory tests were acquired on each visit. In total, more than 18 million data points were generated (Fig. 1b); the cohort is described by Zhou et al.¹³ and Schüssler-Fiorenza Rose et al.¹⁴. For the purpose of this study, we focused on healthy quarterly visits ($n = 624$), searching for biological molecules that are associated with age.

To understand aging patterns between and within people, we performed three types of analyses: (1) identification of markers and pathways that cross-sectionally associated with the age of individuals across the cohort; (2) identification of molecular aging differences between participants who were IR and insulin sensitive (IS); and (3) identification of personal markers and pathways that changed with age for each individual and how these differed between individuals (Fig. 1c).

We first systematically searched for markers that strongly correlated with the median age of each participant in the cohort. From the 624 healthy visits, we analyzed the median expression of 10,343 genes, 306 plasma proteins, 722 metabolites, 62 cytokines, 6,909 microbes (at the level of 16S rRNA) and 51 clinical markers and performed Spearman correlation tests with the median age of the participant. After correcting for body mass index (BMI) and sex, we found 184 molecules from different ‘omes’ that showed different trends and levels of association with age (Fig. 2a, Extended Data Fig. 1a and Supplementary Table 1); some were reported previously, whereas many others had not been reported. For example, from the clinical laboratory data, estimated glomerular filtration rate, which is known to decrease with age¹⁵, correlated negatively with age in our cohort (Spearman, $\rho = -0.6$, false discovery rate (FDR) = 5.5×10^{-6}). Several growth factors, such as platelet-derived growth factor (PDGF)-BB (Spearman, $\rho = 0.36$, FDR = 0.017) and vascular endothelial growth factor (VEGF)-D (Spearman, $\rho = 0.26$, FDR = 0.128) positively correlated with age. Other isoforms of VEGF and PDGF growth factors have been reported to correlate with age^{16,17}. After multiple-hypothesis corrections, we found 87 biological molecules and microbial features that correlated with age at FDR < 0.1 and 184 molecules and microbes at FDR < 0.2. Among the 184 molecules and microbial features, 160 were metabolites and 40% of these were lipids, a class of molecule known to change with age¹⁸ (Extended Data Fig. 1b). Xenobiotics such as hippuric acid, 2-aminophenol sulfate and quinic acid (18%) and amino acids (16%) were other groups of metabolites that correlated with age.

¹Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA. ²These authors contributed equally: Sara Ahadi, Wenyu Zhou. *e-mail: mnsnyder@stanford.edu




Fig. 1 | Integrative Personal Omics Profiling (iPOP) cohort sampling and data collection for aging analyses. **a**, Study design. A total of 106 participants were profiled by multiomic assays at their quarterly healthy visits over the course of up to 48 months. The numbers in green boxes indicate the number of months since enrollment for the quarterly visits. **b**, Graphical illustration of sample collection, multiomic assays and data generation for participants, including 35 participants who were IR, 31 participants who were IS and 40 participants with an unclassified insulin status. Data from a total of 624 healthy visits were analyzed. Omic assays included proteomics using sequential window acquisition of all theoretical fragment ion spectra mass spectrometry (SWATH-MS), metabolomics using untargeted liquid chromatography mass spectrometry (LC-MS) and transcriptomics and microbial profiling using next-generation sequencing. **c**, Plot of the collection dates for all participants (left), participant characteristics (middle) and participant age (right). Red, IR; green, IS; dark gray, unknown insulin status; blue, the participant was included in the longitudinal study and was analyzed for personal aging trends (ageotyped); light gray, the participant was not included in the longitudinal cohort owing to insufficient sampling for ageotyping analysis.

Several microbes also correlated with age. These included the gut bacteria *Clostridium* cluster IV whose abundance increased with age (Spearman, $\rho=0.38$, $FDR=0.023$), consistent with the complex dynamics of different *Clostridium* bacteria during aging¹⁹. The genus *Blautia* was also positively associated with age, consistent with a recent microbiome study that showed that *Blautia hansenii* can be used to predict chronological age²⁰.

We sometimes observed that molecules of similar function had different associations with age. For instance, the insulin-related growth factors IGF2R and IGFALS were inversely correlated with age (Spearman, $\rho=-0.33$, $FDR=0.0943$ and Spearman, $\rho=0.31$, $FDR=0.0943$, respectively), whereas two other insulin-signaling-related molecules, IGFLR1 and IGFBP7 (Spearman, $\rho=0.15$ and 0.14 , respectively), correlated positively with age. The complexity of insulin growth factors and signaling molecules in aging has been reported previously²¹. In addition, the inverse correlations of fetuin-B (Spearman, $\rho=-0.31$, $FDR=0.0944$) and vitamin K-dependent protein S (PROS1) (Spearman, $\rho=-0.30$, $FDR=0.121$) with age are consistent with previous studies^{22,23}.

To understand the biological pathways associated with age, we analyzed significant molecules (Supplementary Table 1) whose level

of expression correlated with age at $P<0.05$ (including 563 genes) using Ingenuity Pathway Analysis and found that both reported and unreported pathways were associated with age (Fig. 2b and Supplementary Table 2). Acute-phase response signaling, high mobility group box 1 (HMGB1) signaling, Toll-like receptor signaling and the coagulation pathway increased with age, consistent with reported increased levels of inflammation and coagulation pathways with age²⁴. We found that different types of molecules contributed to pathway enrichments, underscoring the importance of systematic profiling of many omes. Analysis of an independent cohort of 31 individuals with clinical and proteomics assays (see Methods) validated the positive age correlation of HbA1c, apolipoprotein A-IV protein (ApoA4) and PROS1 (Fig. 2c). Additionally, 99 transcripts that correlated with age in our study were also identified (Supplementary Table 3) in larger cross-sectional studies²⁵.

Because our cohort was well characterized for IR we explored whether individuals who are resistant and sensitive to insulin age differently (IR: median age=57.72 years, $n=35$; IS: median age=54.39 years, $n=31$). We identified ten molecules that significantly correlated with age in the IR group but not in the IS group (Pearson, $FDR<0.2$), and one molecule that significantly correlated




Fig. 2 | Aging molecules and pathways revealed from cross-sectional analyses. **a**, Spearman rho coefficients significantly associated with age for the indicated categories of data. Red indicates positive associations and blue indicates negative associations. **b**, The number of molecules from each of the indicated categories of data (measurement types) belonging to the indicated pathways is shown. The top pathways are shown that were significantly enriched in molecules associated with age. ILK, integrin-linked kinase; RhoGDI, Rho GDP-dissociation inhibitor; Nrf2, NF-E2 p45-related factor 2; AMPK, AMP-activated protein kinase. **c**, Scatter-plots showing the correlation trend of molecules (expression level as y axis) with age (x axis) in two independent cohorts (iPOP, $n = 106$; validation, $n = 31$). Individuals from each cohort are shown as dots and the linear regression coefficient is noted as the red trend line with a gray confidence interval. **d**, Examples of associations that are different between participants who were IR ($n = 35$) and IS ($n = 31$). The x axis shows the age of participants and the y axis shows the normalized values of the measurements (median normalization). Individuals are shown as dots and the linear regression coefficient is noted as the trend line with a gray confidence interval. P values indicate a significant difference between the trends associated with age for the IR and IS groups. **e**, Heat maps of measurements in participants who were IR (top) and IS (bottom). Only measurements that were significantly associated with age in the IR group are presented. In each group, participants are ordered by their age, from left to right. Red indicates increased expression and blue indicates decreased expression. MONO, monocyte count; PLT, platelet count; ALKP, alkaline phosphatase.

with age in the IS group but not in the IR group (Fig. 2d,e and Supplementary Table 4). Of the ten molecules that were significant in the IR and IS groups, nine were also significantly ($P < 0.05$) different between the two groups. These included IgG Fc-binding protein (FCGBP), lumican (LUM; an extracellular matrix protein of human articular cartilage responsible for tissue homeostasis) and non-specific lipid transfer protein (SCP2), which significantly associated positively with age in the IR group. The xenobiotic 2-aminophenol sulfate showed a strong positive correlation in individuals who were IR. The phosphoglucomutase 1 gene (*PGM1*) was one of the genes most frequently observed to have different expression in aging in IR and IS ($P = 4.75 \times 10^{-5}$, on the basis of the interaction term of the linear model describing different trends in the two groups) and is involved in the breakdown and synthesis of glycogen and the regulation of glucose 1-phosphate and glucose 6-phosphate²⁶. Monocyte counts were positively correlated and platelet counts were negatively correlated with age in individuals who were IR. Alkaline phosphatase showed a significant positive correlation only in the IS group. These results demonstrate that individuals who are IR and IS follow different aging patterns at the molecular level.

The frequent sampling of individuals over a potentially actionable time frame (Fig. 3a), which we arbitrarily defined as less than 2 years, enabled us to study how individuals change with time at a personal level. We focused on 43 individuals who had at least five healthy visits spanning at least 700 d, which was sufficient for identifying analytes that changed with time (see Supplementary Table 5). Molecules and microbes that significantly associated with age were identified by rank-based linear regression analysis using Spearman correlation of both host and microbial analytes (Supplementary Tables 5 and 6 for analysis by alternative linear mixed-effects models). Within the 1,200-d window, the number of molecules associated with age was independent of the number of sampling days (Extended Data Fig. 2 and Supplementary Table 7). For example, individual ZOZOW1T had 56 visits over 2,349 d and had 775 molecules significantly associated with aging within the 1,200-d period ($P < 0.05$; Fig. 3b), whereas individual ZN3TBJM had 9 visits over 1,141 d and had 2,438 molecules associated with aging within the 1,200-d period (Fig. 3c).

Pathway analysis of personal aging molecules in different individuals revealed distinct aging pathways for each individual. For example, individual ZOZOW1T had significant enrichments in LXR/RXR activation, acute-phase response signaling, and complement and coagulation cascade pathways (Fig. 3b and Supplementary Table 8), whereas individual ZN3TBJM had cardiac hypertrophy signaling as one of the top enriched pathways identified on the basis of molecules correlating with aging (Fig. 3c and Supplementary Table 9). Furthermore, different individuals had distinct trends in their gut microbial changes over time. For example, individual ZOZOW1T had 56 significant changes across taxonomy levels in gut microbes, whereas individual ZN3TBJM had only 6 significant changes during this time, 5 of which were not observed in ZOZOW1T (Supplementary Table 5).

To understand how molecules that correlated with age in a population compared to their trends in individuals, we specifically examined clinical laboratory markers that might also provide clinically useful insights (Fig. 3d). For the six clinical markers significantly associated with age at the cross-sectional population level, we observed that these markers did not always associate with aging at an individual level, and often showed associations that were significantly reversed from the population trend. For example, HbA1C correlated positively with aging across the cohort but was only positively correlated in 18 individuals (4 significantly, $P < 0.05$) and was negatively correlated with aging at the individual level in 24 individuals (4 significantly, $P < 0.05$). Creatinine also had a positive correlation with aging at the population level, but interestingly had a negative correlation in more than 70% of the individuals we studied.

Thus, although molecules can show a significant trend at a population level, at a personal level these trends can be the opposite.

To examine whether variation in aging associations at the personal level could be a result of the individual's lifestyle, we systematically examined lifestyle and medication changes for people with those records available. Twenty-eight participants logged dietary habits using 25 food categories at each visit (see Methods). Correlation analysis of the food category changes (duration in days in the study) with the age association of clinical markers showed that there was no significant correlation between food intake and time for the food categories, with one exception (Supplementary Table 10), indicating that dietary intakes are generally stable and dietary alteration is not responsible for the longitudinal changes in the clinical markers observed in our cohort. However, one participant had an increase in soft drink intake and decreased blood urea nitrogen (BUN) with increased monocyte levels and red blood cell distribution width (RDW).

We also examined physical activity, medication and BMI changes for the participants. Thirty-one participants filled out the International Physical Activity Questionnaire (IPAQ) with each visit. Changes to medications (diabetic medications and statins) were tracked for all 43 participants through self-reporting and electronic health records. Two of the 31 participants significantly reduced physical activity over time (one with low effect). One individual started metformin and another added a third diabetic medication to their regimen; two individuals started taking statins and one person stopped taking statins. Two of 43 participants lost weight. Thus, the vast majority of participants (96.4%, 93.5% and 88.4%) reported no significant change in diet, activity or medications, respectively. Taking these data together with the food data for the vast majority of participants, it is unlikely that the changes we observed were due to lifestyle or medications.

To determine whether lifestyle could affect age-associated clinical markers directly, we examined whether participants who deviated from the population trend had an alteration in lifestyle, BMI or medication. We found that there were four participants who had a significantly negative correlation of HbA1c with age, indicative of an improvement in glucose metabolism during the study. Two of these had undergone diet restriction and the other two had lost weight, as reflected by their lifestyle surveys (Fig. 3d). Moreover, there were 12 participants with significantly decreased associations with age for BUN or creatinine, suggesting an improvement in kidney function over time, as both of these clinical markers typically increase with age. We found that eight of those individuals were consistently taking statins throughout the entire study, whereas four were not; the fraction of individuals who were on statins and had decreased creatinine was significantly different ($P = 0.043$) from the fraction of individuals whose creatinine increased with age. Interestingly, one person who lost weight during the study improved in all six clinical markers. These data suggest that, at least in some cases, obvious interventions can improve clinical markers, whereas for other cases, the source of their improvement remains unclear.

Finally, as an independent examination of age, we used the published phenotypic age formula to assess whether a reported aging metric changes with time at a personal level^{27,28}. Although overall phenotypic age increased with age as expected (slope = 1.07), consistent with the results presented above, the individual phenotypic age slopes differed among the different participants, with 15 participants even showing negative values (Fig. 3e). These results using an independent metric further suggest that individuals are aging at different rates as well as potentially through different biological mechanisms.

These results indicate that individuals can have distinct aging patterns, or ageotypes. To systematically analyze the individual aging patterns, we further analyzed the 608 molecules that significantly correlated with age in at least six individuals (see Supplementary




Fig. 3 | Personal aging markers show personalized aging patterns that are distinct from those of cross-sectional aging markers. **a**, Graphical illustration of the personal aging trend analysis based on longitudinal measurements of analytes in the same individual. **b,c**, Longitudinal analysis of aging in participants Z0ZOWIT (**b**) and ZN3TBJM (**c**). Top, representative scatter plots showing longitudinal levels of analytes significantly associated with days elapsed since study onset. Longitudinal measurements of an analyte in one individual are shown as dots and the rank-based linear regression coefficient is noted as the trend line with a gray confidence interval. A2M, α -2-macroglobulin; SERPINF2, serpin family F member 2; MEF2A, myocyte enhancer factor 2A; MAP3K6, mitogen-activated protein kinase 6 (all measurements from transcriptomic RNA-seq). Bottom, examples of enriched pathways identified from aging-associated analytes. Darker shades represent increased levels over the course of the study. **d**, Spearman rho coefficients comparing personal associations and cross-sectional associations ($n=106$) for six clinical laboratory analytes. Participants analyzed for their personal aging trends are displayed along the x axis in the same order for each panel. For each clinical analyte, the Spearman rho coefficient obtained from cross-sectional association is marked with an asterisk. Color coding (pink, blue and green) for groups was based on clustering analysis using coefficients of the six clinical laboratory values. Individuals with changes in diet, exercise and weight management are indicated graphically in the A1C panel. CR, creatinine; MONOAB, absolute count of monocytes. **e**, Phenotypic age regression on the chronological age of individuals ($n=43$). The gray trend line is the overall regression line for the cohort. The colored lines are the fitted regression lines for each individual.

age or IR and IS status (Extended Data Figs. 3–5 and Supplementary Table 18).

Human aging is due to a combination of factors from genetics to environmental factors, such as an individual's lifestyle and exposure, and as such is very heterogeneous³³. Our study investigates aging at the individual level by frequent sampling and deep molecular profiling over a time period that is potentially actionable. In contrast to other studies, which have focused on epigenomics and telomeres, we found many more different types of molecules, such as transcripts, proteins and metabolites as well as the microbiome, that were associated with age, including 87 significant molecules (Spearman, $FDR < 0.1$) and 84 significant pathways ($P < 0.05$). Immune and inflammation pathways were found to be among the major pathways that change with aging.

We have studied aging patterns of individuals who are IR and IS using multiomics data and identified several molecules that correlate differently in these individuals. Many of these reside in the inflammation and related immune pathways in individuals with IR, suggesting that individuals with IR may experience increased inflammation with age more rapidly than individuals with IS.

This rich multiomic dataset on multiple visits of 43 individuals provided the opportunity to study personal aging markers and patterns. Longitudinal profiling for up to 4 years and with five or more samples per individual provided the required statistical power to help find the markers and pathways that correlate with aging. The general trends of the personal aging markers followed those of the cross-sectional markers; however, detailed analyses of the clinical markers revealed personal differences, with some individuals displaying negative trends of aging markers. Some of these differences were likely due to interventions in the personal life of the individuals, such as lifestyle changes (such as, weight loss), suggesting that these markers are actionable and that lifestyle changes can be used to alter an individual's aging pattern. In other cases, the source of the improvement in aging markers (such as, the four cases where creatinine was decreased) is not clear.

Here, distinct pathways associated with age in each individual have been revealed. For example, in individual ZOZOW1T, the coagulation pathway was the pathway most strongly correlated with age. However, for individual ZN3TBJM, the cardiac hypertrophy pathway was the pathway most correlated with aging, suggesting alterations in heart function. These differences may be due to individual genetics, personal life habits, medical history or life stresses. We monitored lifestyle (diet and physical activity) and medication for most participants and did not observe obvious changes for most (with the exceptions noted), indicating that differences are either intrinsic or due to more subtle lifestyle changes.

In addition to individual ageotypes, we defined four main pathways enriched with aging using the longitudinal data from 43 individuals. Our analysis shows that some individuals fall strongly into one or more of these aging pathways, suggesting that they have distinct ageotypes. Improvements in lifestyle can presumably affect one or more ageotypes. Indeed, individuals ZL9BTWF and ZK112BX lost weight during the course of our study and improved in multiple clinical markers associated with multiple pathways. It is possible that improvements in ageotype can be targeted at the individual pathway level (such as, immune function or metabolic pathways) using selective interventions (such as, drugs) or in aggregate using broad lifestyle changes. The availability of personal time-dependent aging markers potentially enables aging to be acted upon at an individual level.

Online content

Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and

code availability are available at <https://doi.org/10.1038/s41591-019-0719-5>.

Received: 21 March 2019; Accepted: 26 November 2019;

Published online: 13 January 2020

References

- Lopez-Otin, C., Blasco, M. A., Partridge, L., Serrano, M. & Kroemer, G. The hallmarks of aging. *Cell* **153**, 1194–1217 (2013).
- Aunan, J. R., Cho, W. C. & Soreide, K. The biology of aging and cancer: a brief overview of shared and divergent molecular hallmarks. *Aging Dis.* **8**, 628–642 (2017).
- Hung, C. W., Chen, Y. C., Hsieh, W. L., Chiou, S. H. & Kao, C. L. Ageing and neurodegenerative diseases. *Ageing Res. Rev.* **9**(Suppl. 1), S36–S46 (2010).
- Kalyani, R. R. & Egan, J. M. Diabetes and altered glucose metabolism with aging. *Endocrinol. Metab. Clin. North Am.* **42**, 333–347 (2013).
- Steenman, M. & Lande, G. Cardiac aging and heart disease in humans. *Biophys. Rev.* **9**, 131–137 (2017).
- Field, A. E. et al. DNA methylation clocks in aging: categories, causes, and consequences. *Mol. Cell* **71**, 882–895 (2018).
- Horvath, S. DNA methylation age of human tissues and cell types. *Genome Biol.* **14**, R115 (2013).
- Lu, A. T. et al. DNA methylation GrimAge strongly predicts lifespan and healthspan. *Aging* **11**, 303–327 (2019).
- Pani, L. N. et al. Effect of aging on A1C levels in individuals without diabetes: evidence from the Framingham Offspring Study and the National Health and Nutrition Examination Survey 2001–2004. *Diabetes Care* **31**, 1991–1996 (2008).
- Bonomini, F., Rodella, L. F. & Rezzani, R. Metabolic syndrome, aging and involvement of oxidative stress. *Aging Dis.* **6**, 109–120 (2015).
- Gutch, M., Kumar, S., Razi, S. M., Gupta, K. K. & Gupta, A. Assessment of insulin sensitivity/resistance. *Indian J. Endocrinol. Metab.* **19**, 160–164 (2015).
- Knowles, J. W. et al. Measurement of insulin-mediated glucose uptake: direct comparison of the modified insulin suppression test and the euglycemic, hyperinsulinemic clamp. *Metabolism* **62**, 548–553 (2013).
- Zhou, W. et al. Longitudinal of host–microbe dynamics in prediabetes. *Nature* **569**, 663–671 (2019).
- Schüssler-Fiorenza Rose, S. M. et al. A longitudinal big data approach for precision health. *Nat. Med.* **25**, 792–804 (2019).
- Wetzels, J. F., Kiemeneij, L. A., Swinkels, D. W., Willems, H. L. & den Heijer, M. Age- and gender-specific reference values of estimated GFR in Caucasians: the Nijmegen Biomedical Study. *Kidney Int.* **72**, 632–637 (2007).
- Edelberg, J. M., Cai, D. & Xaymardan, M. Translation of PDGF cardioprotective pathways. *Cardiovasc. Toxicol.* **3**, 27–35 (2003).
- Pola, R. et al. Age-dependent VEGF expression and intraneural neovascularization during regeneration of peripheral nerves. *Neurobiol. Aging* **25**, 1361–1368 (2004).
- Kolovou, G. et al. Ageing mechanisms and associated lipid changes. *Curr. Vasc. Pharmacol.* **12**, 682–689 (2014).
- Biagi, E. et al. Through ageing, and beyond: gut microbiota and inflammatory status in seniors and centenarians. *PLoS ONE* **5**, e10667 (2010).
- Galkin, F. et al. Human microbiome aging clocks based on deep learning and tandem of permutation feature importance and accumulated local effects. Preprint at *bioRxiv* <https://doi.org/10.1101/507780> (2018).
- Bonafe, M. et al. Polymorphic variants of insulin-like growth factor I (IGF-I) receptor and phosphoinositide 3-kinase genes affect IGF-I plasma levels and human longevity: cues for an evolutionarily conserved mechanism of life span control. *J. Clin. Endocrinol. Metab.* **88**, 3299–3304 (2003).
- Mori, K. et al. Fetuin-A is associated with calcified coronary artery disease. *Coron. Artery Dis.* **21**, 281–285 (2010).
- Reiner, A. P. et al. PROC, PROC and PROS1 polymorphisms, plasma anticoagulant phenotypes, and risk of cardiovascular disease and mortality in older adults: the Cardiovascular Health Study. *J. Thromb. Haemost.* **6**, 1625–1632 (2008).
- Franceschi, C. & Campisi, J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. *J. Gerontol. A Biol. Sci. Med. Sci.* **69**(Suppl. 1), S4–S9 (2014).
- Peters, M. J. et al. The transcriptional landscape of age in human peripheral blood. *Nat. Commun.* **6**, 8570 (2015).
- Bae, E., Kim, H. E., Koh, E. & Kim, K. S. Phosphoglucosyltransferase 1 is necessary for sustained cell growth under repetitive glucose depletion. *FEBS Lett.* **588**, 3074–3080 (2014).
- Liu, Z. et al. A new aging measure captures morbidity and mortality risk across diverse subpopulations from NHANES IV: a cohort study. *PLoS Med.* **15**, e1002718 (2018).
- Liu, Z. et al. Correction: a new aging measure captures morbidity and mortality risk across diverse subpopulations from NHANES IV: a cohort study. *PLoS Med.* **16**, e1002760 (2019).

29. Carter, T. A. et al. Mechanisms of aging in senescence-accelerated mice. *Genome Biol.* **6**, R48 (2005).
30. Ross, G. R. et al. Enhanced store-operated Ca^{2+} influx and ORAI1 expression in ventricular fibroblasts from human failing heart. *Biol. Open* **6**, 326–332 (2017).
31. Kreienkamp, R. et al. A cell-intrinsic interferon-like response links replication stress to cellular aging caused by progerin. *Cell Rep.* **22**, 2006–2015 (2018).
32. Ma, X. et al. The nuclear receptor RXRA controls cellular senescence by regulating calcium signaling. *Aging Cell* **17**, e12831 (2018).
33. Cevenini, E. et al. Human models of aging and longevity. *Expert Opin. Biol. Ther.* **8**, 1393–1405 (2008).

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s), under exclusive licence to Springer Nature America, Inc. 2020

Methods

The data supporting the findings of this study are available within the paper and its Supplementary Information files. The study design, participant recruitment, sample preparation, multiomics assay descriptions and data processing methods are documented by Zhou et al.¹³ and Schüssler-Fiorenza Rose et al.¹⁴. This section describes analyses specific to this study.

Validation cohort. To validate the proteomics and standard clinical tests of the cross-sectional aging study, a cohort of 31 healthy individuals (14 females and 17 males) between the ages of 21 and 75 years (median age of 37 years) was recruited under research study protocol 34563, approved by the Stanford University Institutional Review Board. All participants provided group consent. Participants were recruited through announcements at a scientific conference. This study complies with all relevant ethical regulations and informed written consent was obtained from all participants. Supplementary Table 19 lists information on each individual, such as sex, age, ethnicity, fasting glucose, HbA1c and some of the clinical lipid results. Briefly, plasma and serum were prepared from blood collected from fasted individuals. The plasma samples were profiled using SWATH-MS¹⁵ and clinical test results were collected from the serum. Molecules associated with age were identified as described in the next section.

Cross-sectional correlations with aging. For molecular associations with aging, the median value of each measurement at all healthy baselines per participant was tested for association with median age values. For aging association, Spearman correlation was calculated with the `cor.test()` function in the R stats package (v.3.5.0).

Individuals in our cohort were classified by an SSPG test into IR and IS groups, in which 35 individuals with SSPG values higher than 150 mg dl⁻¹ were considered as being IR and 31 with an SSPG lower than 150 mg dl⁻¹ were designated as being IS¹².

To compare correlations specific to IR and IS subgroups, the median values from 35 participants who were IR and 31 participants who were IS were used, treating BMI as a confounding factor, using the `pcor.test()` function in the R `ppcor` package (v.1.1). The IR and IS difference in the aging association was further tested in rank-based linear regression models with an interaction term as implemented in `rfit(Exp ~ days × IR/IS)` in the R `rfit` package (v.0.23.0), where `Exp` represents the normalized value per molecule.

Pathway-enrichment analysis. Pathway-enrichment analysis was performed using Qiagen Ingenuity Pathway Analysis (IPA). For cross-sectional studies, significant molecules ($P < 0.05$, before multiple-hypothesis correction) were used for analysis to consider contributions from all omics data types. Fisher's exact test in the IPA software was used for calculating the FDR and a cutoff of FDR < 0.05 was set for pathways. IPA and interpretation were based on the comprehensive and manually curated content of the Ingenuity Knowledge Base, which organizes biological interactions and functional annotations created from primary literature and public and third-party databases (Qiagen; <https://www.qiagenbioinformatics.com/products/ingenuitypathway-analysis>).

Linear regression analysis for personal aging trends. Longitudinal measurements from each one were linearly transformed before normalizing to a standard distribution $N \sim (0,1)$ across all healthy visits. For each individual, a delta change at each visit was calculated by subtracting measurements from the initial baseline value. Accordingly, the day since onset was calculated as the number of days from the first baseline measurement. For each individual, a rank-based (nonparametric) linear regression was implemented to correlate the change in value versus the day since onset for each analyte. The correlation coefficient ρ and P values of Spearman correlation were calculated using the `rcorr()` function in the R `Hmisc` package (v.4.1-1). The slope and Wald statistic score of the regression line were calculated using the `rfit()` function in the R `rfit` package (v.0.23.0). A Wald score was used to test the general linear hypothesis as follows:

$$H_0 : M\beta = 0 \text{ versus } H_A : M\beta \neq 0$$

where β is the regression coefficient and M is the data matrix.

For dietary eating habits, a validated short dietary assessment³⁴ was used to collect participants' food frequency changes on the same day as the visit. We collected more than 300 fully completed instruments for 28 individuals during the study. The frequency responses to 25 food categories were converted to numeric values before downstream analysis. The 25 food categories included were: (1) slices of bread or rolls, (2) biscuits, (3) cakes, scones, sweet pies or pastries, (4) breakfast cereal, (5) fresh fruit, (6) cooked green vegetables, (7) cooked root vegetables, (8) raw vegetables or salad, (9) chips, (10) potatoes, pasta or rice, (11) meat, (12) meat products, (13) poultry, (14) white fish, (15) oil-rich fish, (16) cheese, (17) beans or pulses, (18) sweets or chocolates, (19) ice cream, (20) crisps or savory snacks, (21) fruit juice, (22) soft or fizzy drinks, (23) cakes, scones or sweet pies, (24) pastries and (25) biscuits. The frequencies of 6+ times per day, 4–5 times per day, 2–3 times per day, once per day, 5–6 times per week, 2–4 times per week, once per week, 1–3 times per month and less than once per month were converted

to 0–8, respectively. The associations of these eating habits with aging (in days) during the study followed the Spearman correlation analysis as above. In this case, a positive ρ indicated a decrease in the frequency of food intake, whereas a negative ρ indicated an increase in the frequency of food intake.

To score changes in medications, we specifically examined statins and other cholesterol-lowering medications (including atorvastatin, fluvastatin, Niaspan, cholestyramine, fenofibrate and gemfibrozil), as well as metformin and other glucose-control medications (including insulin, acarbose, albiglutide, alogliptin, dapagliflozin, glimepiride, linagliptin, metformin and sitagliptin). We manually scanned each participant's electronic health record that aligned with the study window (from the enrollment date of each participant to the last visit analyzed) and examined medication prescription start and end dates to assess changes in medication over the course of the study.

In a second method, we used linear mixed-effects models to account for the dependence within participants. To avoid bias caused by different time windows measured for each individual, we focused on changes that occurred within the first 1,200 d. Results are summarized in Supplementary Table 6. We used `rmcor`, a method that is close to a null multilevel model of varying intercept and a common slope for each individual, and specifically tests for a common association between variables (expression or abundance of an analyte and number of days since onset) within each participant. `rmcorr` calculates an effect size to appropriately represent the degree to which each participant's data is reflected by the common slope of the best-fit parallel lines. The `rmcorr` method takes a meta-analytic approach and calculates `rrm` (error degrees of freedom (d.f.)), P value (determined by the F ratio: $F(\text{measure d.f.} (1), \text{error d.f.})$) and a 95% confidence interval (CI) of effect sizes. When the relationship between variables (expression or abundance of an analyte and number of days since onset) varies widely across participants, the `rmcorr` effect size will be near zero with the CI also near zero. When there is no strong heterogeneity across participants and parallel lines provide a good fit, the `rmcorr` effect size will be large, with a tight CI. To calculate the intraclass correlation coefficient, we first linearly transformed each analyte (when applicable) and standardized the total variation to 1, before applying the `lmer()` function from the `lme4` R package, with the formula as `lmer(Exp ~ 1 + days + A1C + SSPG + FPG + (1|SubjectID), data = dataset, REML = FALSE)`, in which `Exp` was linearly transformed and standardized values of each analyte were obtained. FPG was the fasting plasma glucose as one of the clinical lab tests, and restricted maximum likelihood (REML) was one method implemented in the `lmer` function. We thereby calculated the intraclass correlation coefficient as the proportion of total variation explained by subject structure in the cohort by `Vrandom subject / (Vrandom subject + Vrandom residual)`, where V was the variance from the corresponding component extracted by `VarCov()`.

Physical activity was assessed using the IPAQ short form, a validated measure of physical activity³⁵. The IPAQ was scored per protocol using an automated scoring Excel worksheet to obtain the estimated total metabolic equivalent of task minutes per week of exercise. `Proc reg` in SAS 9.4 was used to regress the estimated metabolic equivalent of task minutes per week on time for each individual to determine whether there had been a significant change in physical activity.

Phenotypic age was calculated using the equation provided by Liu et al.^{27,28} that uses chronological age and nine biomarkers, including albumin, creatinine, glucose, log (C-reactive protein), lymphocyte percent, mean cell volume, RDW, ALKP and white blood cell count. `Proc reg` in SAS 9.4 was used to regress phenotypic age on age to determine individual slopes. `Proc mixed` was used to determine the overall sample slope for the model using a linear mixed model that regressed phenotypic age on age and allowed for intercept and age as random effects grouped by participant. We used the maximum-likelihood method of estimation, the between-within degrees of freedom method and an unstructured covariance matrix.

Personal aging pathways, major grouping and ageotypes. For pathway enrichment for ageotype analysis, 608 molecules (Supplementary Table 11) that were significant in at least six individuals ($P < 0.05$, before multiple-hypothesis correction) were counted to balance the individual versus group components of the pattern. Pathway-enrichment analysis was performed using Qiagen IPA as above and 107 canonical pathways and 147 toxicity pathways were found to be significantly enriched ($P < 0.05$; Supplementary Table 12). To group those pathways into superfamilies of pathways, we merged two pathways in a pairwise fashion into one if the two had identical molecules for more than 60% of the pathway of the smaller size. Supplementary Table 13 lists the largest four superfamilies and the components of pathways merged. We defined ageotype patterns on the basis of the four superfamilies of pathways. We calculated the magnitude of the ageotype as the sum of regression coefficients in the linear regression models in which the molecules were associated with aging (in days) from each superfamily. If data were missing, individual molecules were excluded and had no effect on this summed slope. Low magnitudes meant a relatively low (or reserved) magnitude of increased changes over time compared to the highest changes that we observed in the cohort. Furthermore, average Wald scores were calculated as the mean of Wald statistics across all molecules from each superfamily, to test the probability of β , the regression coefficient of any molecule in that superfamily, being different from zero.

Summary of statistics. The statistical method for each analysis is described in each of the above sections. To summarize, for aging associations, the correlation coefficient and *P* value were calculated by Spearman correlation and trends of normalized molecular expression to the days since onset were calculated by rank-based linear regression. Multiple-hypothesis testing was performed to count the dimensions of molecules being tested. Additionally, the Wald score was used to test the probability of the regression coefficient being different from zero. Also see the Nature Research Reporting Summary for details of statistics and analysis.

Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability

Raw data included in this study are hosted on the NIH Human Microbiome 2 project site (<https://portal.hmpdacc.org>) with no restrictions on their use. Exome sequencing data are also available at dbGaP under study accession [phs001719.v1.p1](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE101171). Both raw and processed data are also hosted on the Stanford iPOP site (<http://med.stanford.edu/ipop.html>). For additional information regarding the study, please contact the corresponding author.

References

- Lean, M. E. J., Anderson, A. S., Morrison, C. & Currall, J. Evaluation of a dietary targets monitor. *Eur. J. Clin. Nutr.* **57**, 667–673 (2003).
- Hagströmer, M., Oja, P. & Sjöström, M. The International Physical Activity Questionnaire (IPAQ): a study of concurrent and construct validity. *Public Health Nutr.* **9**, 755–762 (2006).

Acknowledgements

We thank numerous colleagues who contributed to this study, including all the authors of the Zhou et al. study¹³. We thank the Stanford Center for Genomics and Personalized Medicine (SCGPM) for providing the computing and data storage resources. We also

thank the Jackson Laboratory for Genomic Medicine for contributing to this project. This work was supported by grants from the National Institutes of Health (NIH) Common Fund Human Microbiome Project (U54DK102556), by a grant award to the SCGPM Genome Sequencing Service Center (NIH, S10OD020141), by the Stanford Clinical and Translational Science Award to Spectrum (NIH, UL1TR001085) and by the Diabetes Genomics and Analysis Core of the Stanford Diabetes Research Center (P30DK116074). S.M.S.-F.R. was supported by NIH grant K08 ES028825.

Author contributions

S.A., W.Z., M.R.S., K.C. and M. Avina performed experimental bench work and collected data. W.Z. and S.A. analyzed the data and generated results, with contributions from S.M.S.-F.R. M. Avina managed and coordinated the biobank sample inventory. M. Ashland and W.Z. managed the cohort and coordinated clinical visits. A.B. and M.S. obtained funding and provided additional study resources. S.A., W.Z., A.B., S.M.S.-F.R. and M.S. wrote and revised the manuscript. M.S. supervised the overall study.

Competing interests

M.S. is a cofounder of Personalis, Qbio, Sensomics, Mirvie, Filtricine, Protos and January. He is on the scientific advisory board of Jungla, Jupiter and Genapsys.

Additional information


Extended data is available for this paper at <https://doi.org/10.1038/s41591-019-0719-5>.

Supplementary information is available for this paper at <https://doi.org/10.1038/s41591-019-0719-5>.


Correspondence and requests for materials should be addressed to M.S.

Peer review information Michael Basson was the primary editor on this article and managed its editorial process and peer review in collaboration with the rest of the editorial team.


Reprints and permissions information is available at www.nature.com/reprints.




Extended Data Fig. 1 | Significant analytes associated with aging in the cross-section cohort (n = 106). Left: Number of significant multi-omics molecules correlating with age based on p-value threshold (before multiple hypothesis correction). Right: The categories and their corresponding percentage (frequency) of metabolites significantly associated with the age. Significance is based on the Spearman rank tests.




Extended Data Fig. 2 | Scatter plot of number of significant molecules with the age in longitudinal data of 43 individuals. (Intentionally blank).



Extended Data Fig. 3 | Scatter plot showing associations of the magnitude (cumulative trend values of contributing molecules) of each ageotpes with BMI based on 43 individuals. Associations are not significant. Significance is calculated in the linear regression model.



Extended Data Fig. 4 | Scatter plot showing associations of the magnitude (cumulative trend values of contributing molecules) of each ageotypes with Age based on 43 individuals. Associations are not significant. Significance is calculated in the linear regression model.



Extended Data Fig. 5 | Scatter plot showing associations of the magnitude (cumulative trend values of contributing molecules) of each ageotypes with insulin-resistant/sensitive status based on 43 individuals. Associations are not significant. Significance is calculated in the linear regression model.

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see [Authors & Referees](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted
Give P values as exact values whenever suitable.
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection

No software is used.

Data analysis

R/Python standard packages with custom scripts. R packages that are used in the study include stats V3.5.0, ppcor V1.1.1, Rfit, V0.23.0, Hmisc V.4.1-1. Additional software are also used, including Qiagen Ingenuity Pathway Analysis, SAS 9.4.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

Data will be available at <https://portal.hmpdacc.org>

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

- Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	Our study is done in two levels of cross sectional and longitudinal analysis: For cross sectional analysis (n = 106) we used median value for all time points of all participants and for longitudinal analysis we used longitudinal data on participants with 5 data points and more. For group-wise comparison (IR vs IS), we used median value of all time points of participants in each group. and used statistical analyses to take the sample size into account. For our analyses focusing on individual characters (n = 43), we examined on those participants who had at least five independent samplings that spanned at least 700 days in our study. For both analyses, we rely on significant test to ensure the sample size is sufficient to draw conclusions.
Data exclusions	As frequently used in microbiome studies, for microbiome analyses, to capture major changes across the whole cohort, we focused on prevalent taxa and genes out of all mapped ones, excluding those that were present in less than half of the cohort.
Replication	To control data generation reproducibility, we included multiple aliquots for selected samples anonymously in different batches of all omic assays, and make sure replicates were similar to each other than to any other samples.
Randomization	Samples were randomly arranged by computing program into various batches of omics assay.
Blinding	Each sample was labeled with an numeric ID whose annotation was kept blinded during data collection and analyses.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

Methods

- n/a | Involved in the study
- Antibodies
 - Eukaryotic cell lines
 - Palaeontology
 - Animals and other organisms
 - Human research participants
 - Clinical data

- n/a | Involved in the study
- ChIP-seq
 - Flow cytometry
 - MRI-based neuroimaging

Human research participants

Policy information about [studies involving human research participants](#)

Population characteristics	55 participants in this study were female and 51 male, with ages ranging from 25 to 75 yrs old and BMI 25–40 kg/m ² . More information were provided in Methods and Supplemental Table.
Recruitment	The recruitment details were documented in Zhou, et al., Nature, 2019. Briefly, participants were recruited through placement of advertisements in local newspapers and radio stations seeking ‘prediabetic volunteers’ at risk of T2D for a longitudinal multi-omic study. Screening in the CTRU entailed collection of clinical history, physical examination, anthropometric measurements, and fasting blood tests for exclusions. All different ages of male and female participants were recruited.
Ethics oversight	Stanford University IRB has approved the study.

Note that full information on the approval of the study protocol must also be provided in the manuscript.